Inve India ▾

Bharat Parenterals share price & results

Bharat Parenterals Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q4 FY26
Ownership as of
Sept 2026

Vadodara-based export-led manufacturer of sterile injectables, tablets and capsules for anaesthetics, antibiotics and CNS, with CDMO and branded-generics subsidiaries in complex injectables

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue55.5 ₹ crore−41.2% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin12.3 %−3.9 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit3.7 ₹ crore−63.4% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity-4.90 %+2.4 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-0.48 %+15.9 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)-11.19 %−28.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

2 of 7 judged targets kept · 11 open · verdicts reflect calls analysed to Q4 FY26.

Bharat Parenterals Limited management guidance track record on Inve: 18 targets tracked across analysed earnings calls (2 achieved, 5 missed, 11 open).

TargetOriginal wordingSaidLatest callVerdict
Innoxel FY26 Revenuearound INR70 crores
Call transcript, Q4 FY25 · 14 May 2025		Q4 FY25Q4 FY26:Achieved. Full year FY26 revenue was INR 72.4 crores, exceeding the original and revised guidance.
Call transcript, Q4 FY26 · 19 May 2026		Achieved
Innoxel Operational Break-evenoperationally break even in this FY '26 at Innoxel
Call transcript, Q4 FY25 · 14 May 2025		Q4 FY25Q4 FY26:Missed. Full year FY26 EBITDA was a loss of INR 6.9 crores, despite turning positive in Q4.
Call transcript, Q4 FY26 · 19 May 2026		Missed
Varenyam Bio Lifesciences Operational Timelineoperational by 2027
Call transcript, Q4 FY25 · 14 May 2025		Q4 FY25Q4 FY26:Significantly delayed. Commissioning now targeted for Sep 2027, with first commercial supply in Q4 FY29.
Call transcript, Q4 FY26 · 19 May 2026		Delayed

Source: Inve Guidance Tracker for Bharat Parenterals Limited · to Q4 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

5 of Bharat Parenterals Limited's 18 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 15 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,886.8 +4.69% · +₹84.6

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +51.1% 1Y

₹1.0k₹1.5k₹2.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 12 Nov 2025Q4 FY26 — 19 May 2026

1Y: ₹1,248.45 on 24 Oct 2025 → ₹1,886.8. High ₹2,149.8 (28 Sept 2026), low ₹890.5 (2 Feb 2026).

Previous close
₹1,802.2
Market cap
₹1.2k Cr
52-week range
₹890.5 – ₹2,149.8
One year
+48.69%
Return on equity (TTM to Jun 2026)
-4.90%

Overview

Symbol
NSE:BPLPHARMA
Exchange
NSE
Currency
INR

What Bharat Parenterals Limited does

Based on the company's own presentations, annual report and earnings calls.

Bharat Parenterals (BPL) is a 1992-founded, Vadodara (Gujarat) manufacturer of finished dosage forms — small-volume parenterals, powder-for-injection, tablets, capsules, creams, ointments, gels and oral suspensions — sold across anaesthetics, antibiotics, CNS, anti-malarial, anti-retroviral and anti-TB therapy areas to 40+ export markets and domestic institutional tenders. Its 55.9%-owned subsidiary Innoxel Lifesciences is a USFDA- and EU-GMP-cleared CDMO making complex/specialty injectables (liposomal, extended-release, oncology) for regulated US/EU partners under out-licensing and CMO/CDO arrangements. Wholly-owned Varenyam Healthcare markets branded institutional generics (anaesthesia, critical care, pain) through its own field force to hospitals across India, while wholly-owned Varenyam Bio Lifesciences is building an EU-GMP-targeted complex-injectables facility in Vadodara aimed at other regulated (SRA/PICs) markets.

Segments

  • BPL Standalone
  • Innoxel Lifesciences
  • Varenyam Healthcare
  • Varenyam Bio Lifesciences
Manufacturing facility (BPL standalone)
300,000 sq.ft. in Vadodara, Gujarat — 3 dedicated production blocks (General, Beta-Lactam, Cephalosporin)
Installed capacity (FY26, mn units/yr)
General block: Tablets 1,845 · Capsules 1,120 · Injections 103 · Liquids 46 · Powder 27; Beta-Lactam: Tablet/Capsule 900/900, Dry Syrup 46, Powder for Injection 45; Cephalosporin: Tablet/Capsule 660/518, Dry Syrup 51, Powder for Injection 45
Capacity utilization (FY26)
General block 48.5% · Beta-Lactam 21% · Cephalosporin 24.3%
Export presence
40+ countries
Product registrations/filings
350+ cumulative filings; 48 new registrations and 214 dossiers submitted in FY26
Standalone manpower
500+ technical and non-technical staff
Founded 1992Headquarters Vadodara, GujaratEmployees 500 (FY26)

How the price took the results

close before → close after

Q4 FY26
−1.5%
19 May
Q2 FY26
+1.4%
12 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Bharat Parenterals Limited

Free account: one company. Everything above stays public.

Write why you follow Bharat Parenterals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Bharat Parenterals Limited

Guides on how to read this kind of business and the numbers that matter.